Valuation: Celltrion, Inc.

Market Cap 42,528B 31.08B 26.94B 25.46B 23.11B 43.32B 2,982B 43.58B 304B 117B 1,512B 117B 114B 4,821B P/E 2026 *
26.9x
P/E 2027 * 23x
Enterprise Value 44.74B 32.7M 28.34M 26.79M 24.32M 45.58M 3.14B 45.85M 320M 124M 1.59B 123M 120M 5.07B EV / Sales 2026 *
8.11x
EV / Sales 2027 * 6.92x
Free-Float
60.59%
Yield 2026 *
0.42%
Yield 2027 * 0.47%
Manager TitleAgeSince
Chief Executive Officer 65 19/03/2015
Chief Executive Officer 42 25/03/2021
President 51 12/02/2026
Director TitleAgeSince
Chairman 68 -
Director/Board Member 61 31/03/2005
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
+0.52%+0.64%-1.36%+26.89% 45.91B
-0.32%+4.61%+43.90%+26.98% 44.25B
-4.36%-5.66%+338.30%+516.88% 41.99B
+0.46%-0.83%+6.38%+73.76% 39.58B
-0.17%-3.22%+10.29%+38.69% 31.08B
-0.65%+5.14%+25.61%+120.17% 17.21B
+3.30%-5.03% - - 16.27B
+2.14%+7.73%+21.69%+38.86% 14.96B
+0.86%+9.05%+0.47%-33.54% 13.42B
Average +0.23%+1.18%+55.66%+101.09% 29.41B
Weighted average by Cap. -0.25%+0.31%+70.17%+122.60%

Financials

2026 *2027 *
Net sales 5,518B 4.03B 3.5B 3.3B 3B 5.62B 387B 5.65B 39.44B 15.24B 196B 15.15B 14.81B 626B 6,337B 4.63B 4.01B 3.79B 3.44B 6.46B 444B 6.49B 45.29B 17.5B 225B 17.4B 17.01B 718B
Net income 1,536B 1.12B 973M 919M 835M 1.56B 108B 1.57B 10.97B 4.24B 54.61B 4.22B 4.12B 174B 1,785B 1.3B 1.13B 1.07B 970M 1.82B 125B 1.83B 12.76B 4.93B 63.47B 4.9B 4.79B 202B
Net Debt 2,215B 1.62B 1.4B 1.33B 1.2B 2.26B 155B 2.27B 15.83B 6.12B 78.76B 6.08B 5.95B 251B 1,355B 990M 858M 811M 736M 1.38B 95.01B 1.39B 9.68B 3.74B 48.19B 3.72B 3.64B 154B
Logo Celltrion, Inc.
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!